Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b

2017 ◽  
Vol 33 (1) ◽  
pp. 249-255 ◽  
Author(s):  
Kazuhiko Hayashi ◽  
Masatoshi Ishigami ◽  
Yoji Ishizu ◽  
Teiji Kuzuya ◽  
Takashi Honda ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Direct Sequencing ◽  
Virus Genotype ◽  
Genotype 1B ◽  
Invader Assay

scholarly journals Drug resistant variants of hepatitis C virus genotype 1b in Russia: analysis of aminoacid substitutions in NS5a and core proteins

2018 ◽  
Vol 10 (4) ◽  
pp. 30-36
Author(s):  
V. S. Kichatova ◽  
A. A. Karlsen ◽  
O. V. Isaeva ◽  
S. A. Solonin ◽  
E. Yu. Malinnikova ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Amino Acid ◽  
Direct Sequencing ◽  
Virus Genotype ◽  
Genotype 1B ◽  
Core Proteins ◽  
Clinically Significant ◽  
N 93 ◽  
Direct Acting

Aim. To determine the prevalence of amino acid substitutions in hepatitis C virus NS5a and core proteins which areassociated with resistance to direct-acting antivirals and interferon in genotype 1b (HCV-1b) strains circulating in Russia. Materials and methods. Nucleotide sequences of NS5a (n=93) and core (n=30) of HCV-1b were obtained using direct sequencing of respective amplified genome fragments. The search for resistance associated substitutions was performed for amino acid positions 28, 29, 30, 31, 32, 58, 62, 92, 93 of NS5a, and 70 and 91 amino acid positions of core proteins, respectively. Results. The total proportion of HCV-1b strains carrying resistance associated substitutions in NS5a was 22,6% (21/93). The total detection rate of L31M and Y93H substitutions that are associated with resistance to the majority of NS5a inhibitors was 10,8%. Less clinically significant substitutions L28M, R30Q, P58S/T, A92T were detected too. The proportion of infections caused by HCV-1b strains that are potentially resistant both to interferon and NS5a inhibitors was 10% (10/30). Conclusion. Testing of HCV-1b infected patients for background resistance profile could be a useful tool to prevent the choosing of initially ineffective treatment regimen.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

2018 ◽  
Vol 49 (3) ◽  
pp. 256-263 ◽  
Author(s):  
Yasue Takeuchi ◽  
Norio Akuta ◽  
Hitomi Sezaki ◽  
Fumitaka Suzuki ◽  
Shunichiro Fujiyama ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Virus Genotype ◽  
Genotype 1B

Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)

2018 ◽  
Vol 30 (9) ◽  
pp. 1073-1076 ◽  
Author(s):  
Vasily Isakov ◽  
Dzmitry Paduta ◽  
Rolando M. Viani ◽  
Jeffrey V. Enejosa ◽  
Viktor Pasechnikov ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virus Genotype ◽  
Genotype 1B ◽  
Chronic Hepatitis C Virus
Sign in / Sign up

Export Citation Format

Share Document